PolyNovo Limited (ASX: PNV) — Stock Profile

About PNV (ASX: PNV)

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company's commercial focus centres on wound care and tissue regeneration, with its pipeline extending into hernia repair, abdominal wall reconstruction, and plastics and reconstructive device products.

Its flagship product, NovoSorb Biodegradable Temporising Matrix, is a dermal matrix used to regenerate dermis lost through extensive surgery, trauma, or burn. The company is also developing NovoSorb MTX for single-stage grafting in burns, chronic, and surgical wounds, a Beta Cell implant designed as a novel intracutaneous ectopic pancreas for treating type 1 diabetes, and devices for ventral hernia and complex abdominal wall reconstruction. Formerly known as Calzada Limited, the company adopted the PolyNovo name in November 2014 and was originally incorporated in 1998. It is headquartered in Port Melbourne, Australia.

MFAM Research

No mfam research yet.

Latest Announcements

  • PolyNovo (ASX: PNV) – Files FY2026 Full Year Results
    August 26, 2026
    PolyNovo’s FY26 results demonstrate a company shifting from pure growth mode toward sustainable profitability. While NovoSorb Group revenue increased 16.7% to $138.4 million, the real story lies in the dramatically improved cash generation. Operating cash flow surged to $23.1 million from $3.1 million a year earlier, a sevenfold increase, while free cash flow reached $9.4 […]
  • PolyNovo (ASX: PNV) – PolyNovo Reports FY26 Full Year Results
    August 26, 2026
    PolyNovo delivered solid full year results that demonstrate the medical device company’s progression toward sustainable profitability. Commercial sales reached $138.4 million, a 16.7% increase from the prior year, while the company achieved positive net profit after tax of $7.3 million and generated $23.1 million in operating cash flow. These results underscore PolyNovo’s transition from a […]
  • PolyNovo (ASX: PNV) – PolyNovo Reports FY26 Full Year Results
    August 26, 2026
    PolyNovo Limited reported a significant profit decline for the 2026 financial year despite delivering double-digit revenue growth, highlighting growing pressure on the company’s margins and raising questions about the sustainability of its business model. Revenue increased 16.1% to $149.984 million, yet net profit fell 44.4% to $7.341 million compared to $13.214 million in the prior […]
  • PolyNovo (ASX: PNV) – PolyNovo Second FY26 Trading Update
    July 23, 2026
    PolyNovo delivered revenue of AUD 150 million for FY26, representing 16.1% growth on the prior year and 20.3% in constant currency terms, with the company posting record United States sales in June and significantly strengthening its cash position. The trading update reveals a business at an inflection point, having completed major capital investments while navigating […]
  • PolyNovo (ASX: PNV) – Response to ASX Price Query 3
    May 14, 2026
    PolyNovo Limited responded to an ASX price query on 14 May 2026 after its share price jumped from a low of $1.01 at close on 13 May to a high of $1.19 the following day, accompanied by a significant spike in trading volume. The Australian Securities Exchange sought clarification on whether the company was aware […]

Financial Summary

Price History

Same Industry — HealthcareSame Sub-Industry — Medical Devices
Share This